Zhejiang Garden Biopharmaceutical Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Zhejiang Huayuan Biopharmaceutical Co., Ltd. was established in December 2000 and is a national high-tech enterprise, a national high-tech industrialization demonstration project, and a national resource comprehensive utilization project. The company was listed on the Growth Enterprise Market of Shenzhen Stock Exchange on October 9, 2014, with stock code 300401. The company has always adhered to the development strategy of "building a complete upstream and downstream industry chain of vitamin D3". After more than 20 years of development, it has basically completed the layout of the entire vitamin D3 industry chain and become a production enterprise of the entire vitamin D3 industry chain. The company has four major categories of products: lanolin cholesterol, vitamin D3, 25-hydroxyvitamin D3, and refined lanolin. In the future, the company will also develop a series of fully active vitamin D3 products, building the company into a high-tech enterprise with influence in the pharmaceutical and health fields. The company has three core technologies, namely NF cholesterol production process, vitamin D3 production process, and 25-hydroxyvitamin D3 production process. They have respectively won the second prize of the National Technology Invention Award, the second prize of the National Science and Technology Progress Award, and the first prize of the Zhejiang Province Science and Technology Progress Award. In 2018, due to the relocation of the production base in Xiasha and in order to meet the new requirements of national environmental protection policies, the company took precautions and decided to build Jinxi Science and Technology Park in Jinhua Economic and Technological Development Zone. The park covers an area of 771 acres, and the company's production base will be concentrated in the park. The company has accumulated over 20 years of technology and equipment, adopted advanced automatic control technology, and built Jinxi Science and Technology Park into a highly digital and intelligent modern chemical plant. At the beginning of 2021, facing new opportunities and challenges, the company set new development goals of "one vertical and one horizontal". One vertical: continue to build a complete upstream and downstream industry chain of vitamin D3; one horizontal: utilize the company's industry advantages and marketing channels in the global vitamin market, carry out mergers and integration, and promote the company's business scale and performance to a new level. |
| Headquarter | Jinhua |
| Establish Date | 12/18/2000 |
| Listed Code | 300401.SZ |
| Listed Date | 10/9/2014 |
| Chairman | Shao Xujun. |
| CEO | Ma Huanzheng. |
| Website | www.hybiotech.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
